<code id='9C341C7FEE'></code><style id='9C341C7FEE'></style>
    • <acronym id='9C341C7FEE'></acronym>
      <center id='9C341C7FEE'><center id='9C341C7FEE'><tfoot id='9C341C7FEE'></tfoot></center><abbr id='9C341C7FEE'><dir id='9C341C7FEE'><tfoot id='9C341C7FEE'></tfoot><noframes id='9C341C7FEE'>

    • <optgroup id='9C341C7FEE'><strike id='9C341C7FEE'><sup id='9C341C7FEE'></sup></strike><code id='9C341C7FEE'></code></optgroup>
        1. <b id='9C341C7FEE'><label id='9C341C7FEE'><select id='9C341C7FEE'><dt id='9C341C7FEE'><span id='9C341C7FEE'></span></dt></select></label></b><u id='9C341C7FEE'></u>
          <i id='9C341C7FEE'><strike id='9C341C7FEE'><tt id='9C341C7FEE'><pre id='9C341C7FEE'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:6172
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Empower primary care with adequate payments and technology
          Empower primary care with adequate payments and technology

          PhysicianStormeeWilliamstalkstoanurseandstudentviatheChildren'sHealthTeleHealthSysteminDallas.Childr

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Scientific mystery highlights the blind spots in genomics databases

          AdobeThetwopatientshadbothdiedyoungfromheartproblems.WhenresearcherslookedattheirDNA,theyspottedanot